229 related articles for article (PubMed ID: 31065032)
1. Exploring cellular uptake, accumulation and mechanism of action of a cationic Ru-based nanosystem in human preclinical models of breast cancer.
Piccolo M; Misso G; Ferraro MG; Riccardi C; Capuozzo A; Zarone MR; Maione F; Trifuoggi M; Stiuso P; D'Errico G; Caraglia M; Paduano L; Montesarchio D; Irace C; Santamaria R
Sci Rep; 2019 May; 9(1):7006. PubMed ID: 31065032
[TBL] [Abstract][Full Text] [Related]
2. A new design for nucleolipid-based Ru(III) complexes as anticancer agents.
Montesarchio D; Mangiapia G; Vitiello G; Musumeci D; Irace C; Santamaria R; D'Errico G; Paduano L
Dalton Trans; 2013 Dec; 42(48):16697-708. PubMed ID: 24121739
[TBL] [Abstract][Full Text] [Related]
3. Antiproliferative effects of ruthenium-based nucleolipidic nanoaggregates in human models of breast cancer in vitro: insights into their mode of action.
Irace C; Misso G; Capuozzo A; Piccolo M; Riccardi C; Luchini A; Caraglia M; Paduano L; Montesarchio D; Santamaria R
Sci Rep; 2017 Mar; 7():45236. PubMed ID: 28349991
[TBL] [Abstract][Full Text] [Related]
4. Improving Cytotoxicity against Breast Cancer Cells by Using Mixed-Ligand Ruthenium(II) Complexes of 2,2'-Bipyridine, Amino Acid, and Nitric Oxide Derivatives as Potential Anticancer Agents.
Gaspari APS; da Silva RS; Carneiro ZA; de Carvalho MR; Carvalho I; Pernomian L; Ferreira LP; Ramos LCB; de Souza GA; Formiga ALB
Anticancer Agents Med Chem; 2021; 21(12):1602-1611. PubMed ID: 33081686
[TBL] [Abstract][Full Text] [Related]
5. Breast Cancer Chemotherapeutic Options: A General Overview on the Preclinical Validation of a Multi-Target Ruthenium(III) Complex Lodged in Nucleolipid Nanosystems.
Ferraro MG; Piccolo M; Misso G; Maione F; Montesarchio D; Caraglia M; Paduano L; Santamaria R; Irace C
Cells; 2020 Jun; 9(6):. PubMed ID: 32517101
[TBL] [Abstract][Full Text] [Related]
6. On the Cytotoxicity of Chiral Ruthenium Complexes Containing Sulfur Amino Acids against Breast Tumor Cells (MDA-231 and MCF-7).
Leite CM; de Araujo-Neto JH; Corrêa RS; Colina-Vegas L; Martínez-Otero D; Martins PR; Silva CG; Batista AA
Anticancer Agents Med Chem; 2021; 21(9):1172-1182. PubMed ID: 32838726
[TBL] [Abstract][Full Text] [Related]
7. Vanadium, Ruthenium and Copper Compounds: A New Class of Nonplatinum Metallodrugs with Anticancer Activity.
Leon IE; Cadavid-Vargas JF; Di Virgilio AL; Etcheverry SB
Curr Med Chem; 2017; 24(2):112-148. PubMed ID: 27554807
[TBL] [Abstract][Full Text] [Related]
8. Heterobimetallic Ru(ii)/Fe(ii) complexes as potent anticancer agents against breast cancer cells, inducing apoptosis through multiple targets.
Guedes APM; Mello-Andrade F; Pires WC; de Sousa MAM; da Silva PFF; de Camargo MS; Gemeiner H; Amauri MA; Gomes Cardoso C; de Melo Reis PR; Silveira-Lacerda EP; Batista AA
Metallomics; 2020 Apr; 12(4):547-561. PubMed ID: 32108850
[TBL] [Abstract][Full Text] [Related]
9. Anticancer cationic ruthenium nanovectors: from rational molecular design to cellular uptake and bioactivity.
Mangiapia G; Vitiello G; Irace C; Santamaria R; Colonna A; Angelico R; Radulescu A; D'Errico G; Montesarchio D; Paduano L
Biomacromolecules; 2013 Aug; 14(8):2549-60. PubMed ID: 23705931
[TBL] [Abstract][Full Text] [Related]
10. Half-sandwich Os(ii) and Ru(ii) bathophenanthroline complexes: anticancer drug candidates with unusual potency and a cellular activity profile in highly invasive triple-negative breast cancer cells.
Pracharova J; Novohradsky V; Kostrhunova H; Štarha P; Trávníček Z; Kasparkova J; Brabec V
Dalton Trans; 2018 Sep; 47(35):12197-12208. PubMed ID: 30112527
[TBL] [Abstract][Full Text] [Related]
11. Triple Negative Breast Cancer Preclinical Therapeutic Management by a Cationic Ruthenium-Based Nucleolipid Nanosystem.
Ferraro MG; Bocchetti M; Riccardi C; Trifuoggi M; Paduano L; Montesarchio D; Misso G; Santamaria R; Piccolo M; Irace C
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047448
[TBL] [Abstract][Full Text] [Related]
12. The trans-[Ru(PPh
Becceneri AB; Popolin CP; Plutin AM; Maistro EL; Castellano EE; Batista AA; Cominetti MR
J Inorg Biochem; 2018 Sep; 186():70-84. PubMed ID: 29857173
[TBL] [Abstract][Full Text] [Related]
13. Cytotoxicity and anti-tumor effects of new ruthenium complexes on triple negative breast cancer cells.
Popolin CP; Reis JPB; Becceneri AB; Graminha AE; Almeida MAP; Corrêa RS; Colina-Vegas LA; Ellena J; Batista AA; Cominetti MR
PLoS One; 2017; 12(9):e0183275. PubMed ID: 28898246
[TBL] [Abstract][Full Text] [Related]
14. Ruthenium(II)-Arene Thiocarboxylates: Identification of a Stable Dimer Selectively Cytotoxic to Invasive Breast Cancer Cells.
Stephens LJ; Levina A; Trinh I; Blair VL; Werrett MV; Lay PA; Andrews PC
Chembiochem; 2020 Apr; 21(8):1188-1200. PubMed ID: 31701616
[TBL] [Abstract][Full Text] [Related]
15. Nanoencapsulation of Ruthenium Complex Ru(ThySMet): A Strategy to Improve Selective Cytotoxicity against Breast Tumor Cells in 2D and 3D Culture Models.
Becceneri AB; Fuzer AM; Lopes AC; da Silva PB; Plutin AM; Batista AA; Chorilli M; Cominetti MR
Curr Drug Discov Technol; 2024; 21(2):e060623217687. PubMed ID: 37282638
[TBL] [Abstract][Full Text] [Related]
16. A Liposome Encapsulated Ruthenium Polypyridine Complex as a Theranostic Platform for Triple-Negative Breast Cancer.
Shen J; Kim HC; Wolfram J; Mu C; Zhang W; Liu H; Xie Y; Mai J; Zhang H; Li Z; Guevara M; Mao ZW; Shen H
Nano Lett; 2017 May; 17(5):2913-2920. PubMed ID: 28418672
[TBL] [Abstract][Full Text] [Related]
17. A Review of Ruthenium Complexes Activities on Breast Cancer Cells.
Popolin CP; Cominetti MR
Mini Rev Med Chem; 2017; 17(15):1435-1441. PubMed ID: 28176627
[TBL] [Abstract][Full Text] [Related]
18. Recent advances in ruthenium and platinum based supramolecular coordination complexes for antitumor therapy.
Zhang X; Liu D; Lv F; Yu B; Shen Y; Cong H
Colloids Surf B Biointerfaces; 2019 Oct; 182():110373. PubMed ID: 31376689
[TBL] [Abstract][Full Text] [Related]
19. Ruthenium(II)/(III) DMSO-Based Complexes of 2-Aminophenyl Benzimidazole with In Vitro and In Vivo Anticancer Activity.
Elsayed SA; Harrypersad S; Sahyon HA; El-Magd MA; Walsby CJ
Molecules; 2020 Sep; 25(18):. PubMed ID: 32962014
[TBL] [Abstract][Full Text] [Related]
20. Investigating the Interaction of an Anticancer Nucleolipidic Ru(III) Complex with Human Serum Proteins: A Spectroscopic Study.
Riccardi C; Campanella A; Montesarchio D; Del Vecchio P; Oliva R; Paduano L
Molecules; 2023 Mar; 28(6):. PubMed ID: 36985771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
